Navigation Links
TCT 2010 to have significant impact on interventional cardiology practices and patient care
Date:4/13/2010

NEW YORK, NY -- APRIL 13, 2010 TCT 2010 (Transcatheter Cardiovascular Therapeutics) will provide significant clinical research updates to technologies and practices in interventional cardiology that will directly affect patient care.

The important role of interventional cardiology has figured prominently in recent current events with the announcement that former President Clinton received a heart stent in February at New York-Presbyterian Hospital, followed by the reporting of clinical trial data showing promising results for a heart valve repair device that is inserted via a catheter.

At TCT 2010 (September 21-25 in Washington, DC), late breaking data from clinical trials on the next generation of stents, valve repair and replacement, and the interactions and effectiveness of new medicines will shed light on the best ways to treat patients.

"Catheter-based valve repair and replacement, novel stents, and the effectiveness of various drugs used to treat heart disease are going to be among the major topics at TCT this year," said Gregg W. Stone, MD, Professor of Medicine at Columbia University College of Physicians and Surgeons, Director of Cardiovascular Research and Education at the Center for Interventional Vascular Therapy at NewYork-Presbyterian Hospital/Columbia University Medical Center and Co-Director of the Medical Research and Education Division at the Cardiovascular Research Foundation. TCT is organized by the Cardiovascular Research Foundation.

"Non-surgical aortic valve replacement has the potential to be life saving for people who are at high risk for open heart surgery," Stone said. "As the population ages, this technique may dramatically benefit the quality of life for patients whose aortic valves (the valve through which blood passes from the heart to the rest of the body) fail to function properly. We are hopeful that new trial data that will be presented at TCT will usher in the field of non-operative aortic valve replacement."

This year, TCT will also provide a new program, "TCT in 3," designed specifically for the busy interventional practitioner, which features a concentrated curriculum in a shorter 3 day time frame from Thursday, September 23 through Saturday, September 25. Highlights include live cases, late breaking trials and practice management sessions.

And once again, the conference will feature specific tracks for Cardiac Surgeons and Nurses and Technologists. The Surgeons Course will provide instruction on percutaneous valve repair, hybrid (joint) surgical and interventional approaches to heart disease, percutaneous aortic aneurysm repair methods, with an in-depth course on advanced surgical techniques. The 19th Annual Nurse and Technologist Symposium will detail new trends and cath lab procedures essential for the allied health care professional.

In 2009, TCT was held for the first time in San Francisco, where it attracted record numbers of attendees. 99.4% of physician attendees surveyed stated that TCT increased their knowledge to improve their practice.


'/>"/>

Contact: Judy Romero
jromero@crf.org
212-851-9311
Cardiovascular Research Foundation
Source:Eurekalert

Related medicine news :

1. Sunquest Announces Significant Speaker Schedule for HIMSS 2010
2. Announcing New Book 'Ultimate Procrastination Cure', with a Significantly Different Approach to Stop Procrastinating
3. Mortality rates for pediatric rheumatology patients significantly lower than previously reported
4. Digital mammography delivers significantly less radiation than conventional mammography
5. Counterfeit Internet drugs pose significant risks and discourage vital health checks
6. Advances in Genetic Understanding and Treatment Protocols Lead to Significant Progress in Leukemia and Myeloproliferative Disorders
7. Study finds significantly worse outcomes in cancer patients with cognitive impairment
8. New Actuarial Analysis Shows Senate Bill Would Significantly Raise Premiums
9. MyCareTeam™ Significantly Extends Diabetes Offering to Include Management of Hypertension, Obesity, and Congestive Heart Failure
10. Add Drama and Lift Spirits While Significantly Reducing Energy Cost; Peachtree Introduces the Evolution Series, LED, Energy Efficient Wall Sconce
11. Frost & Sullivan: E-Healthcare in Western Europe Presents a Significant Market Opportunity for Wireless Technologies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/2/2016)... ... May 02, 2016 , ... Beanfields, PBC, ... by partnering with college students at University of Colorado in Boulder to create ... advertising campaigns class in the School of Journalism, who selected Beanfields as the ...
(Date:5/2/2016)... ... ... “Engineering Bubbles,” an oil painting submitted by Canadian radiology resident Dr. Kari ... the Annual Meeting in Los Angeles. The first annual art forum was a platform ... attendees. , “Through art I hope to educate people about radiology and its ...
(Date:5/2/2016)... ... 2016 , ... Dr. Philip Shindler, dentist in Agoura Hills , now ... past, many necessary dental treatments could require multiple appointments to complete. This could mean ... chair time. Not only could this be inconvenient, but it could also be overwhelmingly ...
(Date:5/2/2016)... ... 02, 2016 , ... This week Omega Institute, a premier nonprofit educational retreat ... through October. Omega is offering a record 370 in-person workshops and new online ... such widespread interest in or need for the knowledge and skills we’ve been cultivating ...
(Date:5/2/2016)... ... May 02, 2016 , ... Visceral fat, also known ... the kidneys, liver and pancreas. If not properly addressed, visceral fat can lead ... Internal Medicine, Medical Oncology and Palliative Care, warns against the dangers of visceral ...
Breaking Medicine News(10 mins):
(Date:5/2/2016)... YORK , May 2, 2016 Kalorama ... EMR (Electronic Medical Records) market in a recent white ... sales, vendor switches, Increased physician usage, a growing market are ... were noted in Kalorama,s report EMR 2016: ... report marks Kalorama,s seventh complete study of the EMR ...
(Date:5/2/2016)...  Celsion Corporation (NASDAQ: CLSN ), an ... the first cohort of patients in its Phase ... combining GEN-1, the Company,s DNA-based immunotherapy, with the ... patients with advanced ovarian cancer who will undergo ... the first three patients dosed, GEN-1 plus standard ...
(Date:4/29/2016)... Jersey , April 29, 2016 ... Suite for Life Sciences, Product Development Capabilities in ... Life Science Customer Base . ... provider, today announced the acquisition of Skura Corporation,s ... global leader in adaptive sales enablement technology for ...
Breaking Medicine Technology: